Bioventus Inc. (NYSE:BVS) CFO Sells $53,639.41 in Stock

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 5,479 shares of the firm’s stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $9.79, for a total transaction of $53,639.41. Following the completion of the sale, the chief financial officer now directly owns 131,963 shares of the company’s stock, valued at approximately $1,291,917.77. The trade was a 3.99 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Mark Leonard Singleton also recently made the following trade(s):

• On Tuesday, February 18th, Mark Leonard Singleton sold 6,498 shares of Bioventus stock. The shares were sold at an average price of $10.19, for a total value of $66,214.62.

Bioventus Trading Down 3.0 %

NYSE:BVS traded down $0.29 during midday trading on Tuesday, hitting $9.43. The stock had a trading volume of 231,433 shares, compared to its average volume of 423,781. The stock has a 50-day moving average of $10.11 and a 200 day moving average of $11.01. The company has a market capitalization of $765.29 million, a price-to-earnings ratio of -15.46 and a beta of 0.86. Bioventus Inc. has a one year low of $3.90 and a one year high of $14.38. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on BVS shares. JPMorgan Chase & Co. upgraded Bioventus from an “underweight” rating to a “neutral” rating and boosted their price objective for the company from $12.00 to $13.00 in a report on Tuesday, December 17th. Canaccord Genuity Group restated a “buy” rating and issued a $15.00 price target on shares of Bioventus in a report on Monday, March 17th.

Institutional Investors Weigh In On Bioventus

Hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC raised its holdings in shares of Bioventus by 106.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company’s stock valued at $36,000 after acquiring an additional 1,786 shares in the last quarter. Virtus Fund Advisers LLC purchased a new position in Bioventus during the 3rd quarter valued at about $42,000. Plato Investment Management Ltd bought a new stake in shares of Bioventus in the 4th quarter valued at about $38,000. Quest Partners LLC purchased a new stake in shares of Bioventus in the 3rd quarter worth approximately $51,000. Finally, Quarry LP bought a new position in shares of Bioventus during the third quarter valued at approximately $59,000. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.